Latest News in the pharma Industry

All

Corbus Pharmaceuticals completes Phase II study of JBT-101 for the treatment of cystic fibrosis

Corbus Pharmaceuticals completes Phase II study of JBT-101 for the treatment of cystic fibrosis

1 Jan 2017

Resunab is designed to resolve inflammation thus having the potential to provide significant clinical benefit to CF patients, importantly without immunosuppression.

Read more 
PharmaCyte Biotech’s cannabinoid therapy may offer potential for childhood brain cancers

PharmaCyte Biotech’s cannabinoid therapy may offer potential for childhood brain cancers

1 Jan 2017

Reported research continues to demonstrate the anti-cancer properties of cannabinoids.

Read more 
NIPTE is partner in newly announced National Biopharmaceutical Manufacturing Institute

NIPTE is partner in newly announced National Biopharmaceutical Manufacturing Institute

31 Dec 2016

The participating NIPTE team will primarily focus on biopharmaceutical formulations and product development, and FDA regulatory science.

Read more 
Bavarian Nordic initiates trial of CV301 in combination with nivolumab in patients with lung cancer

Bavarian Nordic initiates trial of CV301 in combination with nivolumab in patients with lung cancer

29 Dec 2016

Study is exploring potential benefits of combining a cancer vaccine and PD-1 checkpoint inhibitor.

Read more 
BioNet receives Thai FDA approval of the world's only available recombinant monovalent acellular Pertussis vaccine

BioNet receives Thai FDA approval of the world's only available recombinant monovalent acellular Pertussis vaccine

29 Dec 2016

BioNet's vaccine is the first recombinant monovalent Pertussis vaccine in the world to receive a MAA for booster indication in adolescents and adults.

Read more 
Provectus Biopharmaceuticals terminates Peter Culpepper as Interim CEO and COO

Provectus Biopharmaceuticals terminates Peter Culpepper as Interim CEO and COO

29 Dec 2016

Investigation reveals improper expense reimbursements.

Read more 
Positive Phase III results of Genentech’s investigational medicine Ocrevus

Positive Phase III results of Genentech’s investigational medicine Ocrevus

28 Dec 2016

Ocrevus is the first and only investigational medicine to show superior efficacy versus comparators in both relapsing and primary progressive multiple sclerosis in clinical studies.

Read more 
FDA approves Shire's Adynovate

FDA approves Shire's Adynovate

28 Dec 2016

New FDA-approved indications for Adynovate provides more hemophilia A patients access to proven prophylaxis with a simple, twice-weekly dosing schedule.

Read more 
FDA places clinical hold on several Phase I trials of Vadastuximab Talirine

FDA places clinical hold on several Phase I trials of Vadastuximab Talirine

28 Dec 2016

Six patients have been identified with hepatotoxicity, including several cases of veno-occlusive disease, with four fatal events.

Read more 
JAMA publishes Mylan and Biocon's proposed biosimilar trastuzumab Phase III data

JAMA publishes Mylan and Biocon's proposed biosimilar trastuzumab Phase III data

27 Dec 2016

Published study results showed an overall response rate of 69.6% for MYL-1401O compared to 64% for branded trastuzumab.

Read more 
Pfizer completes acquisition of small molecule anti-infective business from AstraZeneca

Pfizer completes acquisition of small molecule anti-infective business from AstraZeneca

27 Dec 2016

Agreement includes the commercialization and development rights to the newly approved EU drug Zavicefta (ceftazidime-avibactam).

Read more 
Recursion receives industry awards for drug discovery platform

Recursion receives industry awards for drug discovery platform

27 Dec 2016

Computationally intelligent drug discovery platform receives two Fierce Innovation awards for Biotech Innovation and Best New Product.

Read more